Skip to main content
. Author manuscript; available in PMC: 2020 Feb 12.
Published in final edited form as: Nat Med. 2019 Aug 12;25(9):1422–1427. doi: 10.1038/s41591-019-0542-z

Fig. 2: Tailored combinatorial therapies are effective against tumors that developed bypass resistance to TRK inhibitors.

Fig. 2:

a,b, upper panel, Graph depicting the dynamics of select mutations detected in the cfDNA of the CTRC-NTRK1 positive pancreatic adenocarcinoma (Patient 1, a) and PLEKHA6-NTRK1 positive cholangiocarcinoma (Patient 3, b) patients while treated with a series of targeted therapies. middle panel, The time on treatment, best clinical response achieved (PR: partial response; SD: stable disease based on RECIST v1.1 criteria) and the time of progression (POD) for each of the indicated therapeutic regimens are displayed. Lower panel, Representative scans from the patients at baseline and on treatment with the combination of dabrafenib + trametinib (a) and LOXO-195 + crizotinib (b), respectively.